Melasma is a benign skin condition characterized by symmetric brown-to-gray patches that typically appear on the face, particularly on the cheeks, forehead, nose, and upper lip. Despite being nonmalignant and posing no threat to physical health, melasma develops when melanin—the pigment responsible for skin color—accumulates in excessive amounts, usually triggered by a combination of hormonal changes, sun exposure, and genetic predisposition. A woman in her thirties might notice these patches suddenly worsening after starting birth control pills or during pregnancy, only to find that the discoloration persists for years without proper treatment and management strategies.
Melasma means different things to different people. For some, it’s a cosmetic concern that affects self-confidence; for others, it’s a sign that underlying hormonal or lifestyle factors need attention. The condition follows a chronic, relapsing course, which means that while significant improvement is possible with appropriate treatment, complete clearance without ongoing maintenance is unpredictable. This article explains what melasma actually is, what causes it at a cellular level, why certain people are more prone to developing it, and what the available science tells us about managing this persistent pigmentation disorder.
Table of Contents
- What Is Melasma and How Does It Appear?
- The Multiple Causes of Melasma: Why It Develops
- Who Is Most Likely to Develop Melasma?
- How Melanin Accumulates in the Skin
- The Skin Changes Beyond Just Pigmentation
- Why Melasma Doesn’t Simply Go Away
- What Recent Science Is Revealing About Melasma
- Conclusion
What Is Melasma and How Does It Appear?
Melasma appears as irregularly bordered patches of hyperpigmentation—areas where skin color darkens significantly—usually distributed symmetrically across both sides of the face. The patches are benign and nonpremalignant, meaning they will not transform into skin cancer or pose a systemic health threat. Most commonly, melasma affects the centrofacial region (the center of the face including the cheeks, nose, and forehead), though it can also appear on the malar areas (cheekbones) and mandibular regions (jawline). These patches can range from light tan to deep brown or even gray in appearance, and their borders tend to be irregular rather than sharply defined.
One key distinguishing feature is that melasma is visible and tangible—you can see it, feel it’s there, and it doesn’t fade on its own. Unlike some skin conditions that come and go seasonally, melasma establishes itself and typically requires active intervention to improve. The patches are more noticeable in individuals with darker skin tones, though the condition affects people across all ethnicities. While melasma is purely a pigmentation issue with no systemic consequences, the psychological impact of visible facial discoloration should not be underestimated, particularly in societies where clear, even skin tone is culturally valued.
The Multiple Causes of Melasma: Why It Develops
Melasma does not arise from a single cause but rather from a combination of factors working together. hormonal fluctuations play a particularly significant role: approximately 50% of melasma cases initially present during pregnancy when estrogen and progesterone levels surge dramatically. Women starting oral contraceptives or hormone replacement therapy may also develop melasma, sometimes within weeks of beginning treatment. This hormonal trigger is so reliable that melasma earned the nickname “chloasma” or “mask of pregnancy,” since it frequently appears in expectant mothers. However, not all women who use hormonal medications develop melasma, which points to the importance of other contributing factors like genetics and sun exposure. UV radiation is the second major driver of melasma. When skin is exposed to ultraviolet light, UV rays penetrate the skin and cause lipid peroxidation in cell membranes—essentially a form of oxidative damage. This process generates reactive oxygen species (ROS), which act as signals to melanocytes, the pigment-producing cells in the skin.
In response to these ROS signals, melanocytes ramp up their production of melanin as a protective mechanism. Someone who lives in a high-altitude region with intense year-round sun exposure, or who takes frequent vacations to tropical climates, will likely experience more severe or recurring melasma than someone with minimal sun exposure. UV exposure is cumulative over a lifetime, which explains why melasma often worsens over time rather than spontaneously improving. Genetic predisposition is the third essential factor. Melasma frequently runs in families, particularly in individuals with darker skin types. If your mother or grandmother developed melasma, your risk is considerably higher. Recent research has identified that chronic UV exposure causes dermal fibroblasts—cells in the deeper layers of skin—to become senescent (aged or dysfunctional). These senescent fibroblasts secrete melanogenic factors, particularly Stem Cell Factor and Hepatocyte Growth Factor, which are potent stimulators of melanin production. This means the skin’s own cellular machinery, damaged by years of sun exposure, becomes complicit in worsening pigmentation.
Who Is Most Likely to Develop Melasma?
Melasma is remarkably common in certain populations. Globally, prevalence ranges from 1% in the general population to as high as 9–50% in specific ethnic groups with significant sun exposure, particularly those living near the equator or at high altitudes. In the United States, melasma affects more than 5 million people, with approximately 5–6 million women impacted—a striking gender disparity that reflects the hormonal connection. Roughly 90% of melasma cases occur in women, while only 10% occur in men, underscoring the role of estrogen fluctuations in disease development. The prevalence varies dramatically by geography and ethnicity.
In India, melasma affects approximately 25% of high-risk patients. In Iran, rates range from 16–39.5%, while Morocco reports prevalence up to 37%. Arab-Americans show rates of 13.4–15.5%, and Latino populations demonstrate rates of 8.2–8.8%. High-altitude regions show a mean prevalence of 14.94% based on 2025 data, likely due to increased UV intensity at elevation. Pregnancy significantly increases risk: melasma is present in 15–50% of pregnant patients, though not all cases persist after delivery. A woman of South Asian or Mediterranean descent living at high altitude and currently taking oral contraceptives faces a considerably higher risk than a woman of Northern European ancestry living at a lower latitude.
How Melanin Accumulates in the Skin
Understanding where and how melanin accumulates requires examining the skin’s layered structure. The skin consists of the epidermis (the thin outer layer) and the dermis (the thicker layer beneath). In melasma, increased melanin can appear in the epidermis, the dermis, or both locations simultaneously. When melanin concentrates in the epidermal layer—specifically in the basal and suprabasal keratinocytes—it creates a dark brown appearance with well-defined borders. This epidermal type of melasma is typically easier to see and tends to respond better to treatment because the excess pigment is closer to the skin surface where topical treatments can reach it.
Under a Wood’s lamp, a device that emits ultraviolet light, epidermal melasma appears dramatically darker because the concentrated melanin absorbs the UV light. In contrast, when increased melanin lodges deeper in the dermis, particularly within macrophages (immune cells that have engulfed the pigment), the appearance changes. Dermal melasma looks lighter, more brown or bluish, with blurred rather than sharp borders. When examined under a Wood’s lamp, dermal melasma does not appear darker—it may even look the same or lighter—because the melanin is located too deep for the lamp to fully illuminate. Dermatologically, this distinction matters greatly: dermal melasma typically responds poorly to treatment because the pigment is entrenched in deeper skin layers where many topical remedies cannot penetrate effectively. A person with epidermal melasma might see improvement within weeks of starting treatment, while someone with dermal melasma may require more aggressive interventions or may experience only partial improvement.
The Skin Changes Beyond Just Pigmentation
Melasma involves more than simple melanin excess; it reflects deeper alterations in skin structure. Affected skin exhibits solar elastosis—photodamage caused by years of cumulative sun exposure—which manifests as breakdown of elastic fibers and collagen in the dermis. The basement membrane, a thin structural layer between the epidermis and dermis, becomes disrupted and fragmented in melasma-affected areas. Additionally, affected skin shows increased blood vessel density, meaning more blood vessels are packed into the affected areas compared to surrounding skin. The skin also accumulates elevated numbers of mast cells, immune cells that release inflammatory mediators like histamine.
These deeper pathological changes explain why melasma is not simply a superficial pigmentation problem but rather a comprehensive remodeling of affected skin tissue. However, it’s important to recognize a crucial limitation: these dermal changes do not indicate cancer risk or systemic disease. The skin is responding abnormally to cumulative sun damage and hormonal signals, but this dysregulation remains localized and benign. A person with melasma does not face elevated melanoma risk compared to someone without melasma, though they do share the same general sun-related skin cancer risks as anyone with significant sun exposure. This distinction is clinically important because it allows patients and providers to focus treatment efforts on cosmetic improvement and symptom management rather than cancer prevention, though sun protection remains essential for overall skin health.
Why Melasma Doesn’t Simply Go Away
One of the most frustrating aspects of melasma is its persistent nature. The condition typically follows a chronic, relapsing course, meaning that even after successful treatment, melasma frequently returns. A woman might use hydroquinone cream for several months, see the patches fade significantly, discontinue treatment, and then watch the pigmentation gradually return over the following months—especially if she resumes sun exposure or continues taking hormonal medications. Complete clearance without long-term maintenance is unpredictable; some patients achieve near-complete resolution while others plateau at partial improvement despite aggressive treatment. This unpredictability reflects the condition’s multifactorial nature: even if hormonal triggers are addressed and sun exposure is minimized, genetic predisposition and the underlying cellular changes in the skin remain.
The senescent fibroblasts in the dermis continue to secrete melanogenic factors, perpetuating melanin production even in the absence of active UV exposure or hormonal fluctuations. This means that maintenance therapy—using preventive treatments and rigorous sun protection indefinitely—often becomes necessary rather than optional. Someone who successfully treats melasma might need to apply sunscreen daily, wear protective clothing, and use maintenance topical agents to prevent recurrence. While this ongoing commitment is manageable, it’s not a cure in the traditional sense where treatment stops and the problem resolves. Understanding this chronic relapsing nature helps patients set realistic expectations and commit to long-term management strategies rather than hoping for a one-time fix.
What Recent Science Is Revealing About Melasma
Recent research has significantly advanced understanding of melasma’s underlying mechanisms. In 2025, researchers Miao and colleagues published work classifying melasma as a disorder of epidermal-dermal crosstalk and immune modulation, moving beyond the previous focus on simple melanocyte overactivity. This perspective emphasizes that melasma arises from complex interactions between the epidermis and dermis, between melanocytes and other cell types, and involves dysregulation of immune signaling. The inflammatory component—the elevated mast cells and vascular changes—is now understood as integral to melasma pathophysiology rather than merely a side effect.
Emerging 2025–2026 research from Frontiers journals is examining skin physiological parameters and microflora characteristics in melasma populations, particularly in diverse geographic regions like high-altitude Lhasa, China, where prevalence is notably high. These studies are investigating whether changes in skin surface characteristics, microbiome composition, or other physiological parameters contribute to melasma development or severity. Understanding these novel factors could eventually lead to new prevention and treatment strategies beyond current approaches. As this research continues to evolve, the picture of melasma becomes increasingly nuanced—moving from a simple “too much sun plus hormones equals dark spots” explanation to a recognition of complex systemic and local factors that trigger and sustain the condition.
Conclusion
Melasma is a benign but persistent pigmentation disorder that develops when melanin accumulates abnormally in facial skin, typically triggered by a combination of hormonal changes, UV exposure, and genetic predisposition. The condition affects millions of people worldwide, with particularly high prevalence in populations with darker skin tones and significant sun exposure, though any person of any ethnicity can develop it. Melasma means that the skin’s pigmentation machinery has become dysregulated due to a convergence of triggers—hormonal fluctuations from pregnancy, contraceptives, or hormone replacement; chronic UV damage that signals melanocytes to overproduce pigment; and inherited genetic susceptibility that makes some families more vulnerable than others.
If you’re experiencing melasma, recognize that the condition is medically benign but often requires long-term management. Working with a dermatologist to determine whether your melasma is primarily epidermal or dermal can guide treatment selection, as different types respond differently to available therapies. Implementing strict sun protection, exploring whether hormonal medications might be contributing, and committing to consistent maintenance therapy are the foundations of melasma management. As research continues to illuminate the complex interplay between epidermal-dermal crosstalk, immune modulation, and melanin production, new and more effective treatment options will likely emerge—but for now, understanding what melasma is and why it develops is the first step toward managing it effectively.
